ID   VGFR1_HUMAN             Reviewed;        1338 AA.
AC   P17948; A3E342; A3E344; A8KA71; B0LPF1; B2BF46; B2BF47; B2BF48; B3FR89;
AC   B5A923; F5H5L6; O60722; P16057; Q12954;
DT   01-NOV-1990, integrated into UniProtKB/Swiss-Prot.
DT   03-APR-2007, sequence version 2.
DT   12-OCT-2022, entry version 244.
DE   RecName: Full=Vascular endothelial growth factor receptor 1;
DE            Short=VEGFR-1;
DE            EC=2.7.10.1;
DE   AltName: Full=Fms-like tyrosine kinase 1;
DE            Short=FLT-1;
DE   AltName: Full=Tyrosine-protein kinase FRT;
DE   AltName: Full=Tyrosine-protein kinase receptor FLT;
DE            Short=FLT;
DE   AltName: Full=Vascular permeability factor receptor;
DE   Flags: Precursor;
GN   Name=FLT1; Synonyms=FLT, FRT, VEGFR1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Placenta;
RX   PubMed=2158038;
RA   Shibuya M., Yamaguchi S., Yamane A., Ikeda T., Tojo A., Matsushime H.,
RA   Sato M.;
RT   "Nucleotide sequence and expression of a novel human receptor-type tyrosine
RT   kinase gene (flt) closely related to the fms family.";
RL   Oncogene 5:519-524(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), PROTEIN SEQUENCE OF N-TERMINUS,
RP   SUBCELLULAR LOCATION (ISOFORM 2), INTERACTION WITH VEGFA, AND FUNCTION.
RC   TISSUE=Umbilical vein;
RX   PubMed=8248162; DOI=10.1073/pnas.90.22.10705;
RA   Kendall R.L., Thomas K.A.;
RT   "Inhibition of vascular endothelial cell growth factor activity by an
RT   endogenously encoded soluble receptor.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:10705-10709(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), INTERACTION WITH VEGFA, AND
RP   GLYCOSYLATION.
RC   TISSUE=Umbilical vein;
RX   PubMed=10471394; DOI=10.1006/bbrc.1999.1282;
RA   Herley M.T., Yu Y., Whitney R.G., Sato J.D.;
RT   "Characterization of the VEGF binding site on the Flt-1 receptor.";
RL   Biochem. Biophys. Res. Commun. 262:731-738(1999).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4), FUNCTION IN LIGAND BINDING, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=18593464; DOI=10.1186/ar2447;
RA   Jin P., Zhang J., Sumariwalla P.F., Ni I., Jorgensen B., Crawford D.,
RA   Phillips S., Feldmann M., Shepard H.M., Paleolog E.M.;
RT   "Novel splice variants derived from the receptor tyrosine kinase
RT   superfamily are potential therapeutics for rheumatoid arthritis.";
RL   Arthritis Res. Ther. 10:R73-R73(2008).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), FUNCTION, SUBCELLULAR LOCATION,
RP   TISSUE SPECIFICITY, ROLE IN PREECLAMPSIA, AND INDUCTION.
RX   PubMed=18515749; DOI=10.1161/circresaha.108.171504;
RA   Sela S., Itin A., Natanson-Yaron S., Greenfield C., Goldman-Wohl D.,
RA   Yagel S., Keshet E.;
RT   "A novel human-specific soluble vascular endothelial growth factor receptor
RT   1: cell-type-specific splicing and implications to vascular endothelial
RT   growth factor homeostasis and preeclampsia.";
RL   Circ. Res. 102:1566-1574(2008).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 5; 6; 7 AND 8), ALTERNATIVE SPLICING,
RP   FUNCTION IN PHOSPHORYLATION OF SRC AND CANCER CELL INVASIVENESS, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=20512933; DOI=10.1002/jcb.22584;
RA   Mezquita B., Mezquita J., Pau M., Mezquita C.;
RT   "A novel intracellular isoform of VEGFR-1 activates Src and promotes cell
RT   invasion in MDA-MB-231 breast cancer cells.";
RL   J. Cell. Biochem. 110:732-742(2010).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3).
RA   Mezquita J., Mezquita B., Pau M., Mezquita C.;
RT   "A new VEGFR1 receptor transcript coding for the extracellular domains of
RT   the protein followed by a C-terminal polyserine tail.";
RL   Submitted (DEC-2007) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NHLBI resequencing and genotyping service (RS&G);
RL   Submitted (DEC-2007) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2 AND 3).
RC   TISSUE=Placenta, and Trachea;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057823; DOI=10.1038/nature02379;
RA   Dunham A., Matthews L.H., Burton J., Ashurst J.L., Howe K.L.,
RA   Ashcroft K.J., Beare D.M., Burford D.C., Hunt S.E., Griffiths-Jones S.,
RA   Jones M.C., Keenan S.J., Oliver K., Scott C.E., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Andrews D.T., Ashwell R.I.S., Babbage A.K., Bagguley C.L.,
RA   Bailey J., Bannerjee R., Barlow K.F., Bates K., Beasley H., Bird C.P.,
RA   Bray-Allen S., Brown A.J., Brown J.Y., Burrill W., Carder C., Carter N.P.,
RA   Chapman J.C., Clamp M.E., Clark S.Y., Clarke G., Clee C.M., Clegg S.C.,
RA   Cobley V., Collins J.E., Corby N., Coville G.J., Deloukas P., Dhami P.,
RA   Dunham I., Dunn M., Earthrowl M.E., Ellington A.G., Faulkner L.,
RA   Frankish A.G., Frankland J., French L., Garner P., Garnett J.,
RA   Gilbert J.G.R., Gilson C.J., Ghori J., Grafham D.V., Gribble S.M.,
RA   Griffiths C., Hall R.E., Hammond S., Harley J.L., Hart E.A., Heath P.D.,
RA   Howden P.J., Huckle E.J., Hunt P.J., Hunt A.R., Johnson C., Johnson D.,
RA   Kay M., Kimberley A.M., King A., Laird G.K., Langford C.J., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Lloyd C., Loveland J.E., Lovell J.,
RA   Martin S., Mashreghi-Mohammadi M., McLaren S.J., McMurray A., Milne S.,
RA   Moore M.J.F., Nickerson T., Palmer S.A., Pearce A.V., Peck A.I., Pelan S.,
RA   Phillimore B., Porter K.M., Rice C.M., Searle S., Sehra H.K., Shownkeen R.,
RA   Skuce C.D., Smith M., Steward C.A., Sycamore N., Tester J., Thomas D.W.,
RA   Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M., West A.P.,
RA   Whitehead S.L., Willey D.L., Wilming L., Wray P.W., Wright M.W., Young L.,
RA   Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Beck S., Bentley D.R.,
RA   Rogers J., Ross M.T.;
RT   "The DNA sequence and analysis of human chromosome 13.";
RL   Nature 428:522-528(2004).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Ovary;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1018-1058, AND ALTERNATIVE SPLICING
RP   (ISOFORM 1).
RX   PubMed=3040650;
RA   Matsushime H., Yoshida M.C., Sasaki M., Shibuya M.;
RT   "A possible new member of tyrosine kinase family, human frt sequence, is
RT   highly conserved in vertebrates and located on human chromosome 13.";
RL   Jpn. J. Cancer Res. 78:655-661(1987).
RN   [14]
RP   PARTIAL PROTEIN SEQUENCE, CATALYTIC ACTIVITY, PHOSPHORYLATION AT TYR-914;
RP   TYR-1213; TYR-1242; TYR-1327 AND TYR-1333, MUTAGENESIS OF TYR-914;
RP   TYR-1213; TYR-1242; TYR-1327 AND TYR-1333, AND INTERACTION WITH PLCG; GRB2;
RP   CRK; NCK1 AND PTPN11.
RX   PubMed=9722576; DOI=10.1074/jbc.273.36.23410;
RA   Ito N., Wernstedt C., Engstrom U., Claesson-Welsh L.;
RT   "Identification of vascular endothelial growth factor receptor-1 tyrosine
RT   phosphorylation sites and binding of SH2 domain-containing molecules.";
RL   J. Biol. Chem. 273:23410-23418(1998).
RN   [15]
RP   INTERACTION WITH VEGFA, AUTOPHOSPHORYLATION, CATALYTIC ACTIVITY, FUNCTION
RP   IN PHOSPHORYLATION OF PLCG, AND ABSENCE OF MITOGENIC FUNCTION IN CULTURED
RP   FIBROBLASTS.
RX   PubMed=7824266;
RA   Seetharam L., Gotoh N., Maru Y., Neufeld G., Yamaguchi S., Shibuya M.;
RT   "A unique signal transduction from FLT tyrosine kinase, a receptor for
RT   vascular endothelial growth factor VEGF.";
RL   Oncogene 10:135-147(1995).
RN   [16]
RP   FUNCTION IN CELL MIGRATION, FUNCTION IN VEGFA AND PGF SIGNALING, AND
RP   INDUCTION.
RX   PubMed=8605350;
RA   Barleon B., Sozzani S., Zhou D., Weich H.A., Mantovani A., Marme D.;
RT   "Migration of human monocytes in response to vascular endothelial growth
RT   factor (VEGF) is mediated via the VEGF receptor flt-1.";
RL   Blood 87:3336-3343(1996).
RN   [17]
RP   FUNCTION IN PHOSPHORYLATION OF PLCG AND ACTIVATION OF MAP KINASES,
RP   INTERACTION WITH PLCG, CATALYTIC ACTIVITY, MUTAGENESIS OF LYS-861 AND
RP   TYR-1169, AND PHOSPHORYLATION AT TYR-1169 AND TYR-1213.
RX   PubMed=9299537; DOI=10.1006/bbrc.1997.7327;
RA   Sawano A., Takahashi T., Yamaguchi S., Shibuya M.;
RT   "The phosphorylated 1169-tyrosine containing region of flt-1 kinase (VEGFR-
RT   1) is a major binding site for PLCgamma.";
RL   Biochem. Biophys. Res. Commun. 238:487-491(1997).
RN   [18]
RP   INTERACTION WITH PIK3R1; PTPN11 AND NCK1, AND PHOSPHORYLATION AT TYR-1213.
RX   PubMed=9600074; DOI=10.1006/bbrc.1998.8578;
RA   Igarashi K., Isohara T., Kato T., Shigeta K., Yamano T., Uno I.;
RT   "Tyrosine 1213 of Flt-1 is a major binding site of Nck and SHP-2.";
RL   Biochem. Biophys. Res. Commun. 246:95-99(1998).
RN   [19]
RP   FUNCTION AS NEGATIVE REGULATOR OF KDR-MEDIATED CELL PROLIFERATION.
RX   PubMed=11141500; DOI=10.1016/s0002-9440(10)63965-x;
RA   Dunk C., Ahmed A.;
RT   "Vascular endothelial growth factor receptor-2-mediated mitogenesis is
RT   negatively regulated by vascular endothelial growth factor receptor-1 in
RT   tumor epithelial cells.";
RL   Am. J. Pathol. 158:265-273(2001).
RN   [20]
RP   INTERACTION WITH PIK3R1 AND VEGFA, AUTOPHOSPHORYLATION, PHOSPHORYLATION AT
RP   TYR-1213, SUBCELLULAR LOCATION, IDENTIFICATION BY MASS SPECTROMETRY, AND
RP   GLYCOSYLATION.
RX   PubMed=11513746; DOI=10.1042/0264-6021:3580465;
RA   Yu Y., Hulmes J.D., Herley M.T., Whitney R.G., Crabb J.W., Sato J.D.;
RT   "Direct identification of a major autophosphorylation site on vascular
RT   endothelial growth factor receptor Flt-1 that mediates phosphatidylinositol
RT   3'-kinase binding.";
RL   Biochem. J. 358:465-472(2001).
RN   [21]
RP   FUNCTION IN PGF-MEDIATED CHORIOCARCINOMA CELL PROLIFERATION.
RX   PubMed=11811792; DOI=10.3109/08977190109001086;
RA   Angelucci C., Lama G., Iacopino F., Maglione D., Sica G.;
RT   "Effect of placenta growth factor-1 on proliferation and release of nitric
RT   oxide, cyclic AMP and cyclic GMP in human epithelial cells expressing the
RT   FLT-1 receptor.";
RL   Growth Factors 19:193-206(2001).
RN   [22]
RP   INTERACTION WITH KDR, CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION, AND FUNCTION
RP   IN VEGFA SIGNALING; PHOSPHORYLATION OF PLCG AND ACTIVATION OF
RP   PHOSPHATIDYLINOSITOL KINASE AND PHOSPHOLIPASE C.
RX   PubMed=11312102; DOI=10.1016/s1357-2725(01)00019-x;
RA   Huang K., Andersson C., Roomans G.M., Ito N., Claesson-Welsh L.;
RT   "Signaling properties of VEGF receptor-1 and -2 homo- and heterodimers.";
RL   Int. J. Biochem. Cell Biol. 33:315-324(2001).
RN   [23]
RP   FUNCTION IN SIGNALING VIA ACTIVATION OF THE PHOSPHATIDYLINOSITOL KINASE
RP   PATHWAY AND POSITIVE REGULATION OF ANGIOGENESIS IN RESPONSE TO PGF AND
RP   VEGFA.
RX   PubMed=14633857; DOI=10.2337/diabetes.52.12.2959;
RA   Cai J., Ahmad S., Jiang W.G., Huang J., Kontos C.D., Boulton M., Ahmed A.;
RT   "Activation of vascular endothelial growth factor receptor-1 sustains
RT   angiogenesis and Bcl-2 expression via the phosphatidylinositol 3-kinase
RT   pathway in endothelial cells.";
RL   Diabetes 52:2959-2968(2003).
RN   [24]
RP   INTERACTION WITH PGF AND KDR, FUNCTION IN PHOSPHORYLATION OF KDR; VEGFA AND
RP   PGF SIGNALING, CATALYTIC ACTIVITY, IDENTIFICATION BY MASS SPECTROMETRY, AND
RP   PHOSPHORYLATION AT TYR-1213; TYR-1327 AND TYR-1309.
RX   PubMed=12796773; DOI=10.1038/nm884;
RA   Autiero M., Waltenberger J., Communi D., Kranz A., Moons L., Lambrechts D.,
RA   Kroll J., Plaisance S., De Mol M., Bono F., Kliche S., Fellbrich G.,
RA   Ballmer-Hofer K., Maglione D., Mayr-Beyrle U., Dewerchin M., Dombrowski S.,
RA   Stanimirovic D., Van Hummelen P., Dehio C., Hicklin D.J., Persico G.,
RA   Herbert J.M., Communi D., Shibuya M., Collen D., Conway E.M., Carmeliet P.;
RT   "Role of PlGF in the intra- and intermolecular cross talk between the VEGF
RT   receptors Flt1 and Flk1.";
RL   Nat. Med. 9:936-943(2003).
RN   [25]
RP   INTERACTION WITH CBL AND CD2AP, UBIQUITINATION, AUTOPHOSPHORYLATION IN
RP   RESPONSE TO VEGFA, MUTAGENESIS OF TYR-1333, AND SUBCELLULAR LOCATION.
RX   PubMed=15001553; DOI=10.1096/fj.03-0767fje;
RA   Kobayashi S., Sawano A., Nojima Y., Shibuya M., Maru Y.;
RT   "The c-Cbl/CD2AP complex regulates VEGF-induced endocytosis and degradation
RT   of Flt-1 (VEGFR-1).";
RL   FASEB J. 18:929-931(2004).
RN   [26]
RP   FUNCTION IN VEGFA AND VEGFB SIGNALING; CANCER CELL MIGRATION; INVASIVENESS
RP   AND ACTIVATION OF MAPK1/ERK2 AND MAPK3/ERK1.
RX   PubMed=15735759; DOI=10.1038/sj.onc.1208246;
RA   Fan F., Wey J.S., McCarty M.F., Belcheva A., Liu W., Bauer T.W.,
RA   Somcio R.J., Wu Y., Hooper A., Hicklin D.J., Ellis L.M.;
RT   "Expression and function of vascular endothelial growth factor receptor-1
RT   on human colorectal cancer cells.";
RL   Oncogene 24:2647-2653(2005).
RN   [27]
RP   FUNCTION IN CELL MIGRATION AND PHOSPHORYLATION OF PTK2/FAK1; YES1 AND SRC.
RX   PubMed=16685275; DOI=10.1038/sj.bjc.6603143;
RA   Lesslie D.P., Summy J.M., Parikh N.U., Fan F., Trevino J.G., Sawyer T.K.,
RA   Metcalf C.A., Shakespeare W.C., Hicklin D.J., Ellis L.M., Gallick G.E.;
RT   "Vascular endothelial growth factor receptor-1 mediates migration of human
RT   colorectal carcinoma cells by activation of Src family kinases.";
RL   Br. J. Cancer 94:1710-1717(2006).
RN   [28]
RP   MUTAGENESIS OF ASN-1050.
RX   PubMed=16286478; DOI=10.1074/jbc.m506454200;
RA   Meyer R.D., Mohammadi M., Rahimi N.;
RT   "A single amino acid substitution in the activation loop defines the decoy
RT   characteristic of VEGFR-1/FLT-1.";
RL   J. Biol. Chem. 281:867-875(2006).
RN   [29]
RP   FUNCTION IN PGF AND VEGFA SIGNALING; PHOSPHORYLATION OF AKT1; MAPK3/ERK1
RP   AND MAP KINASES; CHEMOTAXIS AND ACTIVATION OF PHOSPHATIDYLINOSITOL
RP   3-KINASE, AND AUTOPHOSPHORYLATION IN RESPONSE TO PGF AND VEGFA.
RX   PubMed=18079407; DOI=10.1161/atvbaha.107.158022;
RA   Tchaikovski V., Fellbrich G., Waltenberger J.;
RT   "The molecular basis of VEGFR-1 signal transduction pathways in primary
RT   human monocytes.";
RL   Arterioscler. Thromb. Vasc. Biol. 28:322-328(2008).
RN   [30]
RP   FUNCTION IN ENDOTHELIAL CELL SURVIVAL AND ANGIOGENESIS.
RX   PubMed=18583712; DOI=10.1161/circresaha.108.174128;
RA   Nishi J., Minamino T., Miyauchi H., Nojima A., Tateno K., Okada S.,
RA   Orimo M., Moriya J., Fong G.H., Sunagawa K., Shibuya M., Komuro I.;
RT   "Vascular endothelial growth factor receptor-1 regulates postnatal
RT   angiogenesis through inhibition of the excessive activation of Akt.";
RL   Circ. Res. 103:261-268(2008).
RN   [31]
RP   FUNCTION IN CANCER CELL MIGRATION AND ACTIVATION OF MAPK1/ERK2 AND/OR
RP   MAPK3/ERK1.
RX   PubMed=20551949; DOI=10.1038/sj.bjc.6605746;
RA   Taylor A.P., Leon E., Goldenberg D.M.;
RT   "Placental growth factor (PlGF) enhances breast cancer cell motility by
RT   mobilising ERK1/2 phosphorylation and cytoskeletal rearrangement.";
RL   Br. J. Cancer 103:82-89(2010).
RN   [32]
RP   INTERACTION WITH RACK1.
RX   PubMed=21212275; DOI=10.1074/jbc.m110.165605;
RA   Wang F., Yamauchi M., Muramatsu M., Osawa T., Tsuchida R., Shibuya M.;
RT   "RACK1 regulates VEGF/Flt1-mediated cell migration via activation of a PI3-
RT   K/Akt pathway.";
RL   J. Biol. Chem. 286:9097-9106(2011).
RN   [33]
RP   INTERACTION WITH PSEN1 AND PTPRB, DEPHOSPHORYLATION BY PTPRB, MUTAGENESIS
RP   OF VAL-767, AND PROTEOLYTIC CLEAVAGE BY PSEN1 AT VAL-767.
RX   PubMed=22016384; DOI=10.1074/jbc.m111.296590;
RA   Cai J., Chen Z., Ruan Q., Han S., Liu L., Qi X., Boye S.L., Hauswirth W.W.,
RA   Grant M.B., Boulton M.E.;
RT   "gamma-Secretase and presenilin mediate cleavage and phosphorylation of
RT   vascular endothelial growth factor receptor-1.";
RL   J. Biol. Chem. 286:42514-42523(2011).
RN   [34]
RP   FUNCTION AS DECOY RECEPTORS; REGULATION OF VEGFA SIGNALING AND REGULATION
RP   OF KDR ACTIVITY (ISOFORMS 2/3/4), AND ROLE IN PREECLAMPSIA.
RX   PubMed=21752276; DOI=10.1186/2045-824x-3-15;
RA   Ahmad S., Hewett P.W., Al-Ani B., Sissaoui S., Fujisawa T., Cudmore M.J.,
RA   Ahmed A.;
RT   "Autocrine activity of soluble Flt-1 controls endothelial cell function and
RT   angiogenesis.";
RL   Vasc. Cell 3:15-15(2011).
RN   [35]
RP   REVIEW ON FUNCTION AS NEGATIVE REGULATOR OF ANGIOGENESIS DURING EMBRYONIC
RP   DEVELOPMENT; POSITIVE REGULATION OF MACROPHAGE FUNCTION IN ADULTHOOD; ROLE
RP   IN CARCINOGENESIS AND INFLAMMATION.
RX   PubMed=17002866; DOI=10.5483/bmbrep.2006.39.5.469;
RA   Shibuya M.;
RT   "Differential roles of vascular endothelial growth factor receptor-1 and
RT   receptor-2 in angiogenesis.";
RL   J. Biochem. Mol. Biol. 39:469-478(2006).
RN   [36]
RP   REVIEW ON STRUCTURE AND FUNCTION.
RX   PubMed=18680722; DOI=10.1016/j.bbrc.2008.07.121;
RA   Roskoski R. Jr.;
RT   "VEGF receptor protein-tyrosine kinases: structure and regulation.";
RL   Biochem. Biophys. Res. Commun. 375:287-291(2008).
RN   [37]
RP   REVIEW ON ROLE IN ANGIOGENESIS AND CANCER.
RX   PubMed=19230644; DOI=10.1016/j.ceb.2008.12.012;
RA   Lohela M., Bry M., Tammela T., Alitalo K.;
RT   "VEGFs and receptors involved in angiogenesis versus lymphangiogenesis.";
RL   Curr. Opin. Cell Biol. 21:154-165(2009).
RN   [38]
RP   REVIEW ON LIGAND SPECIFICITY; FUNCTION; STRUCTURE; PHOSPHORYLATION AND
RP   SIGNALING.
RX   PubMed=19761875; DOI=10.1016/j.bbapap.2009.09.002;
RA   Grunewald F.S., Prota A.E., Giese A., Ballmer-Hofer K.;
RT   "Structure-function analysis of VEGF receptor activation and the role of
RT   coreceptors in angiogenic signaling.";
RL   Biochim. Biophys. Acta 1804:567-580(2010).
RN   [39]
RP   REVIEW ON ROLE IN CANCER.
RX   PubMed=20127948; DOI=10.1002/cncr.24789;
RA   Schwartz J.D., Rowinsky E.K., Youssoufian H., Pytowski B., Wu Y.;
RT   "Vascular endothelial growth factor receptor-1 in human cancer: concise
RT   review and rationale for development of IMC-18F1 (Human antibody targeting
RT   vascular endothelial growth factor receptor-1).";
RL   Cancer 116:1027-1032(2010).
RN   [40]
RP   REVIEW ON LIGAND SPECIFICITY; FUNCTION; STRUCTURE; PHOSPHORYLATION AND
RP   SIGNALING.
RX   PubMed=21711246; DOI=10.1042/bj20110301;
RA   Koch S., Tugues S., Li X., Gualandi L., Claesson-Welsh L.;
RT   "Signal transduction by vascular endothelial growth factor receptors.";
RL   Biochem. J. 437:169-183(2011).
RN   [41]
RP   REVIEW ON ROLE IN CANCER AND PREECLAMPSIA.
RX   PubMed=21558755; DOI=10.2183/pjab.87.167;
RA   Shibuya M.;
RT   "Involvement of Flt-1 (VEGF receptor-1) in cancer and preeclampsia.";
RL   Proc. Jpn. Acad., B, Phys. Biol. Sci. 87:167-178(2011).
RN   [42]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 132-226 IN COMPLEX WITH VEGFA, AND
RP   DOMAIN.
RX   PubMed=9393862; DOI=10.1016/s0092-8674(00)80456-0;
RA   Wiesmann C., Fuh G., Christinger H.W., Eigenbrot C., Wells J.A.,
RA   de Vos A.M.;
RT   "Crystal structure at 1.7 A resolution of VEGF in complex with domain 2 of
RT   the Flt-1 receptor.";
RL   Cell 91:695-704(1997).
RN   [43]
RP   STRUCTURE BY NMR OF 129-229, X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF
RP   129-229 IN COMPLEX WITH VEGFA, SUBUNIT, AND INTERACTION WITH VEGFA.
RX   PubMed=10543948; DOI=10.1006/jmbi.1999.3134;
RA   Starovasnik M.A., Christinger H.W., Wiesmann C., Champe M.A., de Vos A.M.,
RA   Skelton N.J.;
RT   "Solution structure of the VEGF-binding domain of Flt-1: comparison of its
RT   free and bound states.";
RL   J. Mol. Biol. 293:531-544(1999).
RN   [44]
RP   X-RAY CRYSTALLOGRAPHY (2.45 ANGSTROMS) OF 130-229 IN COMPLEX WITH PGF.
RX   PubMed=14684734; DOI=10.1074/jbc.m313237200;
RA   Christinger H.W., Fuh G., de Vos A.M., Wiesmann C.;
RT   "The crystal structure of placental growth factor in complex with domain 2
RT   of vascular endothelial growth factor receptor-1.";
RL   J. Biol. Chem. 279:10382-10388(2004).
RN   [45]
RP   X-RAY CRYSTALLOGRAPHY (2.71 ANGSTROMS) OF 129-226 IN COMPLEX WITH VEGFB,
RP   INTERACTION WITH VEGFB, SUBUNIT, AND DOMAIN.
RX   PubMed=20501651; DOI=10.1074/jbc.m110.130658;
RA   Iyer S., Darley P.I., Acharya K.R.;
RT   "Structural insights into the binding of vascular endothelial growth
RT   factor-B by VEGFR-1(D2): recognition and specificity.";
RL   J. Biol. Chem. 285:23779-23789(2010).
RN   [46]
RP   VARIANTS [LARGE SCALE ANALYSIS] THR-60; LYS-144; GLN-281; ILE-422; GLN-781;
RP   VAL-938; ALA-982 AND VAL-1061.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Tyrosine-protein kinase that acts as a cell-surface receptor
CC       for VEGFA, VEGFB and PGF, and plays an essential role in the
CC       development of embryonic vasculature, the regulation of angiogenesis,
CC       cell survival, cell migration, macrophage function, chemotaxis, and
CC       cancer cell invasion. Acts as a positive regulator of postnatal retinal
CC       hyaloid vessel regression (Ref.11). May play an essential role as a
CC       negative regulator of embryonic angiogenesis by inhibiting excessive
CC       proliferation of endothelial cells. Can promote endothelial cell
CC       proliferation, survival and angiogenesis in adulthood. Its function in
CC       promoting cell proliferation seems to be cell-type specific. Promotes
CC       PGF-mediated proliferation of endothelial cells, proliferation of some
CC       types of cancer cells, but does not promote proliferation of normal
CC       fibroblasts (in vitro). Has very high affinity for VEGFA and relatively
CC       low protein kinase activity; may function as a negative regulator of
CC       VEGFA signaling by limiting the amount of free VEGFA and preventing its
CC       binding to KDR. Modulates KDR signaling by forming heterodimers with
CC       KDR. Ligand binding leads to the activation of several signaling
CC       cascades. Activation of PLCG leads to the production of the cellular
CC       signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate and
CC       the activation of protein kinase C. Mediates phosphorylation of PIK3R1,
CC       the regulatory subunit of phosphatidylinositol 3-kinase, leading to
CC       activation of phosphatidylinositol kinase and the downstream signaling
CC       pathway. Mediates activation of MAPK1/ERK2, MAPK3/ERK1 and the MAP
CC       kinase signaling pathway, as well as of the AKT1 signaling pathway.
CC       Phosphorylates SRC and YES1, and may also phosphorylate CBL. Promotes
CC       phosphorylation of AKT1 at 'Ser-473'. Promotes phosphorylation of
CC       PTK2/FAK1 (PubMed:16685275). {ECO:0000269|PubMed:11141500,
CC       ECO:0000269|PubMed:11312102, ECO:0000269|PubMed:11811792,
CC       ECO:0000269|PubMed:12796773, ECO:0000269|PubMed:14633857,
CC       ECO:0000269|PubMed:15735759, ECO:0000269|PubMed:16685275,
CC       ECO:0000269|PubMed:18079407, ECO:0000269|PubMed:18515749,
CC       ECO:0000269|PubMed:18583712, ECO:0000269|PubMed:18593464,
CC       ECO:0000269|PubMed:20512933, ECO:0000269|PubMed:20551949,
CC       ECO:0000269|PubMed:21752276, ECO:0000269|PubMed:7824266,
CC       ECO:0000269|PubMed:8248162, ECO:0000269|PubMed:8605350,
CC       ECO:0000269|PubMed:9299537, ECO:0000269|Ref.11}.
CC   -!- FUNCTION: [Isoform 1]: Phosphorylates PLCG.
CC       {ECO:0000269|PubMed:9299537}.
CC   -!- FUNCTION: [Isoform 2]: May function as decoy receptor for VEGFA.
CC       {ECO:0000269|PubMed:21752276}.
CC   -!- FUNCTION: [Isoform 3]: May function as decoy receptor for VEGFA.
CC       {ECO:0000269|PubMed:21752276}.
CC   -!- FUNCTION: [Isoform 4]: May function as decoy receptor for VEGFA.
CC       {ECO:0000269|PubMed:21752276}.
CC   -!- FUNCTION: [Isoform 7]: Has a truncated kinase domain; it increases
CC       phosphorylation of SRC at 'Tyr-418' by unknown means and promotes tumor
CC       cell invasion. {ECO:0000269|PubMed:20512933}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-
CC         [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.10.1;
CC         Evidence={ECO:0000255|PROSITE-ProRule:PRU10028,
CC         ECO:0000269|PubMed:11312102, ECO:0000269|PubMed:12796773,
CC         ECO:0000269|PubMed:7824266, ECO:0000269|PubMed:9299537,
CC         ECO:0000269|PubMed:9722576};
CC   -!- ACTIVITY REGULATION: Present in an inactive conformation in the absence
CC       of bound ligand. Binding of VEGFA, VEGFB or PGF leads to dimerization
CC       and activation by autophosphorylation on tyrosine residues.
CC   -!- SUBUNIT: Interacts with VEGFA, VEGFB and PGF. Monomer in the absence of
CC       bound VEGFA, VEGFB or PGF. Homodimer in the presence of bound VEGFA,
CC       VEGFB and PGF. Can also form a heterodimer with KDR. Interacts (when
CC       tyrosine phosphorylated) with CBL, CRK, GRB2, NCK1, PIK3R1, PLCG, PSEN1
CC       and PTPN11. Probably interacts also with PTPRB. Interacts with RACK1.
CC       Identified in a complex with CBL and CD2AP.
CC       {ECO:0000269|PubMed:10471394, ECO:0000269|PubMed:10543948,
CC       ECO:0000269|PubMed:11312102, ECO:0000269|PubMed:11513746,
CC       ECO:0000269|PubMed:12796773, ECO:0000269|PubMed:14684734,
CC       ECO:0000269|PubMed:15001553, ECO:0000269|PubMed:20501651,
CC       ECO:0000269|PubMed:21212275, ECO:0000269|PubMed:22016384,
CC       ECO:0000269|PubMed:7824266, ECO:0000269|PubMed:8248162,
CC       ECO:0000269|PubMed:9299537, ECO:0000269|PubMed:9393862,
CC       ECO:0000269|PubMed:9600074, ECO:0000269|PubMed:9722576}.
CC   -!- INTERACTION:
CC       P17948; P22681: CBL; NbExp=2; IntAct=EBI-1026718, EBI-518228;
CC       P17948; P46109: CRKL; NbExp=9; IntAct=EBI-1026718, EBI-910;
CC       P17948; P49763: PGF; NbExp=2; IntAct=EBI-1026718, EBI-1037633;
CC       P17948; P27986: PIK3R1; NbExp=3; IntAct=EBI-1026718, EBI-79464;
CC       P17948; Q12913: PTPRJ; NbExp=2; IntAct=EBI-1026718, EBI-2264500;
CC       P17948; P15692: VEGFA; NbExp=4; IntAct=EBI-1026718, EBI-1026643;
CC       P17948; P15692-4: VEGFA; NbExp=3; IntAct=EBI-1026718, EBI-1026691;
CC       P17948-2; PRO_0000391621 [P98160]: HSPG2; NbExp=2; IntAct=EBI-6530464, EBI-6896259;
CC       P17948-2; PRO_0000391622 [P98160]: HSPG2; NbExp=2; IntAct=EBI-6530464, EBI-6896607;
CC   -!- SUBCELLULAR LOCATION: [Isoform 1]: Cell membrane; Single-pass type I
CC       membrane protein. Endosome. Note=Autophosphorylation promotes
CC       ubiquitination and endocytosis.
CC   -!- SUBCELLULAR LOCATION: [Isoform 2]: Secreted
CC       {ECO:0000269|PubMed:8248162}.
CC   -!- SUBCELLULAR LOCATION: [Isoform 3]: Secreted.
CC   -!- SUBCELLULAR LOCATION: [Isoform 4]: Secreted.
CC   -!- SUBCELLULAR LOCATION: [Isoform 5]: Cytoplasm {ECO:0000305}.
CC   -!- SUBCELLULAR LOCATION: [Isoform 6]: Cytoplasm {ECO:0000305}.
CC   -!- SUBCELLULAR LOCATION: [Isoform 7]: Cytoplasm {ECO:0000305}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=8;
CC         Comment=Additional isoforms seem to exist.;
CC       Name=1; Synonyms=Flt1;
CC         IsoId=P17948-1; Sequence=Displayed;
CC       Name=2; Synonyms=sFlt1;
CC         IsoId=P17948-2; Sequence=VSP_002955, VSP_002956;
CC       Name=3; Synonyms=sFlt1-14;
CC         IsoId=P17948-3; Sequence=VSP_041927, VSP_041928;
CC       Name=4;
CC         IsoId=P17948-4; Sequence=VSP_041929, VSP_041930;
CC       Name=5; Synonyms=i15;
CC         IsoId=P17948-5; Sequence=VSP_041985;
CC       Name=6; Synonyms=i18;
CC         IsoId=P17948-6; Sequence=VSP_041984;
CC       Name=7; Synonyms=i21;
CC         IsoId=P17948-7; Sequence=VSP_041983;
CC       Name=8;
CC         IsoId=P17948-8; Sequence=VSP_047759, VSP_047760;
CC   -!- TISSUE SPECIFICITY: Detected in normal lung, but also in placenta,
CC       liver, kidney, heart and brain tissues. Specifically expressed in most
CC       of the vascular endothelial cells, and also expressed in peripheral
CC       blood monocytes. Isoform 2 is strongly expressed in placenta. Isoform 3
CC       is expressed in corneal epithelial cells (at protein level). Isoform 3
CC       is expressed in vascular smooth muscle cells (VSMC).
CC       {ECO:0000269|PubMed:18515749, ECO:0000269|PubMed:20512933}.
CC   -!- INDUCTION: Up-regulated in coculture of VSMC/endothelial cell (EC) or
CC       by direct exposure to VEGF of VSMC monoculture. Up-regulated from the
CC       second trimester of pregnancy to the term and in the placenta of women
CC       with preeclampsia (PE). Up-regulated in monocytes exposed to bacterial
CC       lipopolysaccharide (LPS). {ECO:0000269|PubMed:18515749,
CC       ECO:0000269|PubMed:8605350}.
CC   -!- DOMAIN: The second and third Ig-like C2-type (immunoglobulin-like)
CC       domains are sufficient for VEGFA binding. {ECO:0000269|PubMed:20501651,
CC       ECO:0000269|PubMed:9393862}.
CC   -!- PTM: N-glycosylated. {ECO:0000269|PubMed:10471394,
CC       ECO:0000269|PubMed:11513746}.
CC   -!- PTM: Ubiquitinated after VEGFA-mediated autophosphorylation, leading to
CC       proteolytic degradation. {ECO:0000269|PubMed:15001553}.
CC   -!- PTM: Autophosphorylated on tyrosine residues upon ligand binding.
CC       Autophosphorylation occurs in trans, i.e. one subunit of the dimeric
CC       receptor phosphorylates tyrosine residues on the other subunit.
CC       Phosphorylation at Tyr-1169 is important for interaction with PLCG.
CC       Phosphorylation at Tyr-1213 is important for interaction with PIK3R1,
CC       PTPN11, GRB2, and PLCG. Phosphorylation at Tyr-1333 is important for
CC       endocytosis and for interaction with CBL, NCK1 and CRK. Is probably
CC       dephosphorylated by PTPRB. {ECO:0000269|PubMed:11513746,
CC       ECO:0000269|PubMed:12796773, ECO:0000269|PubMed:9299537,
CC       ECO:0000269|PubMed:9600074, ECO:0000269|PubMed:9722576}.
CC   -!- DISEASE: Note=Can contribute to cancer cell survival, proliferation,
CC       migration, and invasion, and tumor angiogenesis and metastasis. May
CC       contribute to cancer pathogenesis by promoting inflammatory responses
CC       and recruitment of tumor-infiltrating macrophages.
CC   -!- DISEASE: Note=Abnormally high expression of soluble isoforms (isoform
CC       2, isoform 3 or isoform 4) may be a cause of preeclampsia.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. CSF-1/PDGF receptor subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X51602; CAA35946.1; -; mRNA.
DR   EMBL; U01134; AAC50060.1; -; mRNA.
DR   EMBL; AF063657; AAC16449.2; -; mRNA.
DR   EMBL; EU826561; ACF47597.1; -; mRNA.
DR   EMBL; EU368830; ACA62948.1; -; mRNA.
DR   EMBL; DQ836394; ABI53803.1; -; mRNA.
DR   EMBL; DQ836395; ABI53804.1; -; mRNA.
DR   EMBL; DQ836396; ABI53805.1; -; mRNA.
DR   EMBL; EF491868; ABS32268.1; -; mRNA.
DR   EMBL; EF491869; ABS32269.1; -; mRNA.
DR   EMBL; EF491870; ABS32270.1; -; mRNA.
DR   EMBL; EU360600; ACB05747.1; -; mRNA.
DR   EMBL; EU332841; ABY87530.1; -; Genomic_DNA.
DR   EMBL; AK292936; BAF85625.1; -; mRNA.
DR   EMBL; AK300392; BAG62125.1; -; mRNA.
DR   EMBL; AL138712; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL139005; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471075; EAX08431.1; -; Genomic_DNA.
DR   EMBL; CH471075; EAX08432.1; -; Genomic_DNA.
DR   EMBL; BC039007; AAH39007.1; -; mRNA.
DR   EMBL; D00133; BAA00080.1; -; Genomic_DNA.
DR   CCDS; CCDS53860.1; -. [P17948-3]
DR   CCDS; CCDS53861.1; -. [P17948-4]
DR   CCDS; CCDS73556.1; -. [P17948-2]
DR   CCDS; CCDS9330.1; -. [P17948-1]
DR   PIR; A49636; A49636.
DR   PIR; S09982; S09982.
DR   RefSeq; NP_001153392.1; NM_001159920.1. [P17948-2]
DR   RefSeq; NP_001153502.1; NM_001160030.1. [P17948-3]
DR   RefSeq; NP_001153503.1; NM_001160031.1. [P17948-4]
DR   RefSeq; NP_002010.2; NM_002019.4. [P17948-1]
DR   PDB; 1FLT; X-ray; 1.70 A; X/Y=132-226.
DR   PDB; 1QSV; NMR; -; A=129-229.
DR   PDB; 1QSZ; NMR; -; A=129-229.
DR   PDB; 1QTY; X-ray; 2.70 A; T/U/X/Y=129-229.
DR   PDB; 1RV6; X-ray; 2.45 A; X/Y=130-229.
DR   PDB; 2XAC; X-ray; 2.71 A; C/X=129-226.
DR   PDB; 3HNG; X-ray; 2.70 A; A=801-1158.
DR   PDB; 4CKV; X-ray; 2.06 A; X=132-225.
DR   PDB; 4CL7; X-ray; 2.00 A; A/B/C/D=132-225.
DR   PDB; 5ABD; X-ray; 2.00 A; E/I/X=132-226.
DR   PDB; 5EX3; X-ray; 2.41 A; D=827-835.
DR   PDB; 5T89; X-ray; 4.00 A; X/Y=27-656.
DR   PDBsum; 1FLT; -.
DR   PDBsum; 1QSV; -.
DR   PDBsum; 1QSZ; -.
DR   PDBsum; 1QTY; -.
DR   PDBsum; 1RV6; -.
DR   PDBsum; 2XAC; -.
DR   PDBsum; 3HNG; -.
DR   PDBsum; 4CKV; -.
DR   PDBsum; 4CL7; -.
DR   PDBsum; 5ABD; -.
DR   PDBsum; 5EX3; -.
DR   PDBsum; 5T89; -.
DR   AlphaFoldDB; P17948; -.
DR   SMR; P17948; -.
DR   BioGRID; 108609; 67.
DR   DIP; DIP-643N; -.
DR   IntAct; P17948; 177.
DR   MINT; P17948; -.
DR   STRING; 9606.ENSP00000282397; -.
DR   BindingDB; P17948; -.
DR   ChEMBL; CHEMBL1868; -.
DR   DrugBank; DB06626; Axitinib.
DR   DrugBank; DB05932; Denibulin.
DR   DrugBank; DB10770; Foreskin fibroblast (neonatal).
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugBank; DB06101; IMC-1C11.
DR   DrugBank; DB09078; Lenvatinib.
DR   DrugBank; DB06080; Linifanib.
DR   DrugBank; DB07288; N-(4-chlorophenyl)-2-[(pyridin-4-ylmethyl)amino]benzamide.
DR   DrugBank; DB09079; Nintedanib.
DR   DrugBank; DB05913; OSI-930.
DR   DrugBank; DB06589; Pazopanib.
DR   DrugBank; DB09221; Polaprezinc.
DR   DrugBank; DB08896; Regorafenib.
DR   DrugBank; DB15685; Selpercatinib.
DR   DrugBank; DB00398; Sorafenib.
DR   DrugBank; DB01268; Sunitinib.
DR   DrugBank; DB05075; TG-100801.
DR   DrugBank; DB11800; Tivozanib.
DR   DrugBank; DB04879; Vatalanib.
DR   DrugCentral; P17948; -.
DR   GuidetoPHARMACOLOGY; 1812; -.
DR   GlyConnect; 771; 5 N-Linked glycans (6 sites).
DR   GlyGen; P17948; 13 sites, 3 Asn glycans (4 sites), 5 N-linked glycans (6 sites).
DR   iPTMnet; P17948; -.
DR   PhosphoSitePlus; P17948; -.
DR   BioMuta; FLT1; -.
DR   DMDM; 143811474; -.
DR   EPD; P17948; -.
DR   jPOST; P17948; -.
DR   MassIVE; P17948; -.
DR   MaxQB; P17948; -.
DR   PaxDb; P17948; -.
DR   PeptideAtlas; P17948; -.
DR   PRIDE; P17948; -.
DR   ProteomicsDB; 3403; -.
DR   ProteomicsDB; 53530; -. [P17948-1]
DR   ProteomicsDB; 53531; -. [P17948-2]
DR   ProteomicsDB; 53532; -. [P17948-3]
DR   ProteomicsDB; 53533; -. [P17948-4]
DR   ProteomicsDB; 53534; -. [P17948-5]
DR   ProteomicsDB; 53535; -. [P17948-6]
DR   ProteomicsDB; 53536; -. [P17948-7]
DR   ABCD; P17948; 59 sequenced antibodies.
DR   Antibodypedia; 1563; 1679 antibodies from 49 providers.
DR   DNASU; 2321; -.
DR   Ensembl; ENST00000282397.9; ENSP00000282397.4; ENSG00000102755.12. [P17948-1]
DR   Ensembl; ENST00000539099.1; ENSP00000442630.1; ENSG00000102755.12. [P17948-4]
DR   Ensembl; ENST00000541932.5; ENSP00000437631.1; ENSG00000102755.12. [P17948-3]
DR   Ensembl; ENST00000543394.2; ENSP00000437841.1; ENSG00000102755.12. [P17948-8]
DR   Ensembl; ENST00000615840.4; ENSP00000484039.1; ENSG00000102755.12. [P17948-2]
DR   GeneID; 2321; -.
DR   KEGG; hsa:2321; -.
DR   MANE-Select; ENST00000282397.9; ENSP00000282397.4; NM_002019.4; NP_002010.2.
DR   UCSC; uc001usb.4; human. [P17948-1]
DR   CTD; 2321; -.
DR   DisGeNET; 2321; -.
DR   GeneCards; FLT1; -.
DR   HGNC; HGNC:3763; FLT1.
DR   HPA; ENSG00000102755; Tissue enriched (placenta).
DR   MalaCards; FLT1; -.
DR   MIM; 165070; gene.
DR   neXtProt; NX_P17948; -.
DR   OpenTargets; ENSG00000102755; -.
DR   Orphanet; 275555; Preeclampsia.
DR   PharmGKB; PA28180; -.
DR   VEuPathDB; HostDB:ENSG00000102755; -.
DR   eggNOG; KOG0200; Eukaryota.
DR   GeneTree; ENSGT00940000158713; -.
DR   HOGENOM; CLU_000288_49_4_1; -.
DR   InParanoid; P17948; -.
DR   OMA; TRNSGFT; -.
DR   PhylomeDB; P17948; -.
DR   TreeFam; TF325768; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   PathwayCommons; P17948; -.
DR   Reactome; R-HSA-194306; Neurophilin interactions with VEGF and VEGFR.
DR   Reactome; R-HSA-195399; VEGF binds to VEGFR leading to receptor dimerization.
DR   SignaLink; P17948; -.
DR   SIGNOR; P17948; -.
DR   BioGRID-ORCS; 2321; 10 hits in 1106 CRISPR screens.
DR   ChiTaRS; FLT1; human.
DR   EvolutionaryTrace; P17948; -.
DR   GeneWiki; FLT1; -.
DR   GenomeRNAi; 2321; -.
DR   Pharos; P17948; Tclin.
DR   PRO; PR:P17948; -.
DR   Proteomes; UP000005640; Chromosome 13.
DR   RNAct; P17948; protein.
DR   Bgee; ENSG00000102755; Expressed in pericardium and 200 other tissues.
DR   ExpressionAtlas; P17948; baseline and differential.
DR   Genevisible; P17948; HS.
DR   GO; GO:0015629; C:actin cytoskeleton; IDA:HPA.
DR   GO; GO:0005768; C:endosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0005615; C:extracellular space; TAS:ProtInc.
DR   GO; GO:0005925; C:focal adhesion; HDA:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0043235; C:receptor complex; IDA:MGI.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0019838; F:growth factor binding; IPI:UniProtKB.
DR   GO; GO:0036332; F:placental growth factor receptor activity; IDA:UniProtKB.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IBA:GO_Central.
DR   GO; GO:0005021; F:vascular endothelial growth factor receptor activity; IDA:UniProtKB.
DR   GO; GO:0001525; P:angiogenesis; IEA:UniProtKB-KW.
DR   GO; GO:0048514; P:blood vessel morphogenesis; ISS:UniProtKB.
DR   GO; GO:0016477; P:cell migration; IMP:UniProtKB.
DR   GO; GO:0035924; P:cellular response to vascular endothelial growth factor stimulus; IDA:UniProtKB.
DR   GO; GO:0048598; P:embryonic morphogenesis; ISS:UniProtKB.
DR   GO; GO:0002244; P:hematopoietic progenitor cell differentiation; IBA:GO_Central.
DR   GO; GO:1990384; P:hyaloid vascular plexus regression; ISS:UniProtKB.
DR   GO; GO:0002548; P:monocyte chemotaxis; IDA:UniProtKB.
DR   GO; GO:1905563; P:negative regulation of vascular endothelial cell proliferation; IGI:BHF-UCL.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; IMP:UniProtKB.
DR   GO; GO:0030335; P:positive regulation of cell migration; IDA:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; TAS:ProtInc.
DR   GO; GO:0033674; P:positive regulation of kinase activity; IBA:GO_Central.
DR   GO; GO:0043406; P:positive regulation of MAP kinase activity; IDA:UniProtKB.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; IDA:UniProtKB.
DR   GO; GO:0043552; P:positive regulation of phosphatidylinositol 3-kinase activity; IMP:UniProtKB.
DR   GO; GO:0014068; P:positive regulation of phosphatidylinositol 3-kinase signaling; IMP:UniProtKB.
DR   GO; GO:0010863; P:positive regulation of phospholipase C activity; IMP:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IBA:GO_Central.
DR   GO; GO:0048010; P:vascular endothelial growth factor receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0036323; P:vascular endothelial growth factor receptor-1 signaling pathway; IDA:UniProtKB.
DR   Gene3D; 2.60.40.10; -; 7.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR036179; Ig-like_dom_sf.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR013098; Ig_I-set.
DR   InterPro; IPR003599; Ig_sub.
DR   InterPro; IPR003598; Ig_sub2.
DR   InterPro; IPR013106; Ig_V-set.
DR   InterPro; IPR013151; Immunoglobulin.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR001824; Tyr_kinase_rcpt_3_CS.
DR   InterPro; IPR041348; VEGFR-2_TMD.
DR   InterPro; IPR009135; VEGFR1_rcpt.
DR   Pfam; PF07679; I-set; 2.
DR   Pfam; PF00047; ig; 1.
DR   Pfam; PF07714; PK_Tyr_Ser-Thr; 1.
DR   Pfam; PF17988; VEGFR-2_TMD; 1.
DR   PRINTS; PR01833; VEGFRECEPTR1.
DR   SMART; SM00409; IG; 7.
DR   SMART; SM00408; IGc2; 5.
DR   SMART; SM00406; IGv; 2.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF48726; SSF48726; 7.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50835; IG_LIKE; 6.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00240; RECEPTOR_TYR_KIN_III; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Angiogenesis; ATP-binding;
KW   Cell membrane; Chemotaxis; Cytoplasm; Developmental protein;
KW   Differentiation; Direct protein sequencing; Disulfide bond; Endosome;
KW   Glycoprotein; Immunoglobulin domain; Kinase; Membrane; Nucleotide-binding;
KW   Phosphoprotein; Receptor; Reference proteome; Repeat; Secreted; Signal;
KW   Transferase; Transmembrane; Transmembrane helix; Tyrosine-protein kinase;
KW   Ubl conjugation.
FT   SIGNAL          1..26
FT                   /evidence="ECO:0000269|PubMed:8248162"
FT   CHAIN           27..1338
FT                   /note="Vascular endothelial growth factor receptor 1"
FT                   /id="PRO_0000016768"
FT   TOPO_DOM        27..758
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        759..780
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        781..1338
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          32..123
FT                   /note="Ig-like C2-type 1"
FT   DOMAIN          151..214
FT                   /note="Ig-like C2-type 2"
FT   DOMAIN          230..327
FT                   /note="Ig-like C2-type 3"
FT   DOMAIN          335..421
FT                   /note="Ig-like C2-type 4"
FT   DOMAIN          428..553
FT                   /note="Ig-like C2-type 5"
FT   DOMAIN          556..654
FT                   /note="Ig-like C2-type 6"
FT   DOMAIN          661..747
FT                   /note="Ig-like C2-type 7"
FT   DOMAIN          827..1158
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          940..982
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        956..974
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        1022
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10028"
FT   BINDING         833..841
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         861
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   SITE            767..768
FT                   /note="Cleavage; by PSEN1"
FT                   /evidence="ECO:0000305"
FT   MOD_RES         914
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000305|PubMed:9722576"
FT   MOD_RES         1053
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         1169
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:9299537"
FT   MOD_RES         1213
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:11513746,
FT                   ECO:0000269|PubMed:12796773, ECO:0000269|PubMed:9299537,
FT                   ECO:0000269|PubMed:9600074, ECO:0000269|PubMed:9722576"
FT   MOD_RES         1242
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:9722576"
FT   MOD_RES         1309
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:12796773"
FT   MOD_RES         1327
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:12796773,
FT                   ECO:0000269|PubMed:9722576"
FT   MOD_RES         1333
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:9722576"
FT   CARBOHYD        100
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        164
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        196
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        251
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        323
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        402
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        417
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        474
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        547
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        597
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        620
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        625
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        666
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        53..107
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT   DISULFID        158..207
FT   DISULFID        252..311
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT   DISULFID        454..535
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT   DISULFID        577..636
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT   DISULFID        682..731
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT   VAR_SEQ         1..995
FT                   /note="Missing (in isoform 7)"
FT                   /evidence="ECO:0000303|PubMed:20512933"
FT                   /id="VSP_041983"
FT   VAR_SEQ         1..875
FT                   /note="Missing (in isoform 6)"
FT                   /evidence="ECO:0000303|PubMed:20512933"
FT                   /id="VSP_041984"
FT   VAR_SEQ         1..782
FT                   /note="Missing (in isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:20512933"
FT                   /id="VSP_041985"
FT   VAR_SEQ         1..7
FT                   /note="MVSYWDT -> MNSDLLV (in isoform 8)"
FT                   /evidence="ECO:0000303|PubMed:20512933"
FT                   /id="VSP_047759"
FT   VAR_SEQ         8..984
FT                   /note="Missing (in isoform 8)"
FT                   /evidence="ECO:0000303|PubMed:20512933"
FT                   /id="VSP_047760"
FT   VAR_SEQ         518..541
FT                   /note="MASTLVVADSRISGIYICIASNKV -> LPPANSSFMLPPTSFSSNYFHFLP
FT                   (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:18593464"
FT                   /id="VSP_041929"
FT   VAR_SEQ         542..1338
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:18593464"
FT                   /id="VSP_041930"
FT   VAR_SEQ         657..687
FT                   /note="DQEAPYLLRNLSDHTVAISSSTTLDCHANGV -> GEHCNKKAVFSRISKFK
FT                   STRNDCTTQSNVKH (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:8248162"
FT                   /id="VSP_002955"
FT   VAR_SEQ         688..1338
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:8248162"
FT                   /id="VSP_002956"
FT   VAR_SEQ         706..733
FT                   /note="GIILGPGSSTLFIERVTEEDEGVYHCKA -> ELYTSTSPSSSSSSPLSSSS
FT                   SSSSSSSS (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:18515749, ECO:0000303|Ref.7"
FT                   /id="VSP_041927"
FT   VAR_SEQ         734..1338
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:18515749, ECO:0000303|Ref.7"
FT                   /id="VSP_041928"
FT   VARIANT         60
FT                   /note="K -> T (in dbSNP:rs56409818)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042045"
FT   VARIANT         128
FT                   /note="I -> L (in dbSNP:rs35073261)"
FT                   /id="VAR_049719"
FT   VARIANT         144
FT                   /note="E -> K (in dbSNP:rs55974987)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042046"
FT   VARIANT         281
FT                   /note="R -> Q (in dbSNP:rs55687105)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042047"
FT   VARIANT         422
FT                   /note="L -> I (in a lung adenocarcinoma sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042048"
FT   VARIANT         781
FT                   /note="R -> Q (in a glioma low grade oligodendroglioma
FT                   sample; somatic mutation; dbSNP:rs553261958)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042049"
FT   VARIANT         938
FT                   /note="M -> V (in dbSNP:rs35549791)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042050"
FT   VARIANT         982
FT                   /note="E -> A (in dbSNP:rs35832528)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042051"
FT   VARIANT         1061
FT                   /note="L -> V (in a bladder transitional cell carcinoma
FT                   sample; somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042052"
FT   MUTAGEN         767
FT                   /note="V->A: Abolishes proteolytic cleavage by PSEN1."
FT                   /evidence="ECO:0000269|PubMed:22016384"
FT   MUTAGEN         861
FT                   /note="K->M: Abolishes enzyme activity. Abolishes
FT                   interaction with PLCG."
FT                   /evidence="ECO:0000269|PubMed:9299537"
FT   MUTAGEN         914
FT                   /note="Y->F: Reduces phosphorylation at other tyrosine
FT                   residues."
FT                   /evidence="ECO:0000269|PubMed:9722576"
FT   MUTAGEN         1050
FT                   /note="N->D: Strongly increases kinase activity. Increases
FT                   activity in promoting proliferation of endothelial cells."
FT                   /evidence="ECO:0000269|PubMed:16286478"
FT   MUTAGEN         1169
FT                   /note="Y->F: Loss of phosphorylation site. Abolishes
FT                   interaction with PLCG."
FT                   /evidence="ECO:0000269|PubMed:9299537"
FT   MUTAGEN         1213
FT                   /note="Y->F: Loss of phosphorylation site. Abolishes
FT                   interaction with PIK3R1."
FT                   /evidence="ECO:0000269|PubMed:9722576"
FT   MUTAGEN         1242
FT                   /note="Y->F: Loss of phosphorylation site."
FT                   /evidence="ECO:0000269|PubMed:9722576"
FT   MUTAGEN         1327
FT                   /note="Y->F: Loss of phosphorylation site."
FT                   /evidence="ECO:0000269|PubMed:9722576"
FT   MUTAGEN         1333
FT                   /note="Y->F: Loss of phosphorylation site. Abolishes
FT                   interaction with CBL."
FT                   /evidence="ECO:0000269|PubMed:15001553,
FT                   ECO:0000269|PubMed:9722576"
FT   CONFLICT        490
FT                   /note="F -> S (in Ref. 3; AAC16449)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        779
FT                   /note="F -> L (in Ref. 1; CAA35946)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1029
FT                   /note="L -> F (in Ref. 6; ABI53803/ABI53804)"
FT                   /evidence="ECO:0000305"
FT   TURN            130..132
FT                   /evidence="ECO:0007829|PDB:1QSV"
FT   STRAND          135..137
FT                   /evidence="ECO:0007829|PDB:1FLT"
FT   STRAND          140..142
FT                   /evidence="ECO:0007829|PDB:4CL7"
FT   STRAND          144..148
FT                   /evidence="ECO:0007829|PDB:1FLT"
FT   STRAND          150..152
FT                   /evidence="ECO:0007829|PDB:1QSZ"
FT   STRAND          154..156
FT                   /evidence="ECO:0007829|PDB:1FLT"
FT   STRAND          160..162
FT                   /evidence="ECO:0007829|PDB:5ABD"
FT   HELIX           163..165
FT                   /evidence="ECO:0007829|PDB:1QSV"
FT   STRAND          168..171
FT                   /evidence="ECO:0007829|PDB:1FLT"
FT   TURN            172..174
FT                   /evidence="ECO:0007829|PDB:1FLT"
FT   STRAND          175..177
FT                   /evidence="ECO:0007829|PDB:1FLT"
FT   STRAND          181..187
FT                   /evidence="ECO:0007829|PDB:1FLT"
FT   TURN            188..190
FT                   /evidence="ECO:0007829|PDB:1FLT"
FT   STRAND          191..196
FT                   /evidence="ECO:0007829|PDB:1FLT"
FT   HELIX           199..201
FT                   /evidence="ECO:0007829|PDB:1FLT"
FT   STRAND          203..211
FT                   /evidence="ECO:0007829|PDB:1FLT"
FT   STRAND          214..224
FT                   /evidence="ECO:0007829|PDB:1FLT"
FT   HELIX           806..809
FT                   /evidence="ECO:0007829|PDB:3HNG"
FT   HELIX           817..820
FT                   /evidence="ECO:0007829|PDB:3HNG"
FT   HELIX           824..826
FT                   /evidence="ECO:0007829|PDB:3HNG"
FT   STRAND          827..835
FT                   /evidence="ECO:0007829|PDB:3HNG"
FT   STRAND          837..848
FT                   /evidence="ECO:0007829|PDB:3HNG"
FT   HELIX           849..851
FT                   /evidence="ECO:0007829|PDB:3HNG"
FT   STRAND          854..863
FT                   /evidence="ECO:0007829|PDB:3HNG"
FT   HELIX           869..883
FT                   /evidence="ECO:0007829|PDB:3HNG"
FT   STRAND          894..898
FT                   /evidence="ECO:0007829|PDB:3HNG"
FT   STRAND          906..910
FT                   /evidence="ECO:0007829|PDB:3HNG"
FT   HELIX           917..922
FT                   /evidence="ECO:0007829|PDB:3HNG"
FT   HELIX           996..1014
FT                   /evidence="ECO:0007829|PDB:3HNG"
FT   TURN            1015..1017
FT                   /evidence="ECO:0007829|PDB:3HNG"
FT   HELIX           1025..1027
FT                   /evidence="ECO:0007829|PDB:3HNG"
FT   STRAND          1028..1030
FT                   /evidence="ECO:0007829|PDB:3HNG"
FT   HELIX           1032..1034
FT                   /evidence="ECO:0007829|PDB:3HNG"
FT   STRAND          1036..1038
FT                   /evidence="ECO:0007829|PDB:3HNG"
FT   HELIX           1042..1044
FT                   /evidence="ECO:0007829|PDB:3HNG"
FT   TURN            1047..1049
FT                   /evidence="ECO:0007829|PDB:3HNG"
FT   STRAND          1053..1055
FT                   /evidence="ECO:0007829|PDB:3HNG"
FT   HELIX           1063..1065
FT                   /evidence="ECO:0007829|PDB:3HNG"
FT   HELIX           1068..1073
FT                   /evidence="ECO:0007829|PDB:3HNG"
FT   HELIX           1078..1093
FT                   /evidence="ECO:0007829|PDB:3HNG"
FT   HELIX           1107..1113
FT                   /evidence="ECO:0007829|PDB:3HNG"
FT   TURN            1114..1116
FT                   /evidence="ECO:0007829|PDB:3HNG"
FT   HELIX           1127..1136
FT                   /evidence="ECO:0007829|PDB:3HNG"
FT   HELIX           1141..1143
FT                   /evidence="ECO:0007829|PDB:3HNG"
FT   HELIX           1147..1157
FT                   /evidence="ECO:0007829|PDB:3HNG"
SQ   SEQUENCE   1338 AA;  150769 MW;  FF3381EEFAF0787C CRC64;
     MVSYWDTGVL LCALLSCLLL TGSSSGSKLK DPELSLKGTQ HIMQAGQTLH LQCRGEAAHK
     WSLPEMVSKE SERLSITKSA CGRNGKQFCS TLTLNTAQAN HTGFYSCKYL AVPTSKKKET
     ESAIYIFISD TGRPFVEMYS EIPEIIHMTE GRELVIPCRV TSPNITVTLK KFPLDTLIPD
     GKRIIWDSRK GFIISNATYK EIGLLTCEAT VNGHLYKTNY LTHRQTNTII DVQISTPRPV
     KLLRGHTLVL NCTATTPLNT RVQMTWSYPD EKNKRASVRR RIDQSNSHAN IFYSVLTIDK
     MQNKDKGLYT CRVRSGPSFK SVNTSVHIYD KAFITVKHRK QQVLETVAGK RSYRLSMKVK
     AFPSPEVVWL KDGLPATEKS ARYLTRGYSL IIKDVTEEDA GNYTILLSIK QSNVFKNLTA
     TLIVNVKPQI YEKAVSSFPD PALYPLGSRQ ILTCTAYGIP QPTIKWFWHP CNHNHSEARC
     DFCSNNEESF ILDADSNMGN RIESITQRMA IIEGKNKMAS TLVVADSRIS GIYICIASNK
     VGTVGRNISF YITDVPNGFH VNLEKMPTEG EDLKLSCTVN KFLYRDVTWI LLRTVNNRTM
     HYSISKQKMA ITKEHSITLN LTIMNVSLQD SGTYACRARN VYTGEEILQK KEITIRDQEA
     PYLLRNLSDH TVAISSSTTL DCHANGVPEP QITWFKNNHK IQQEPGIILG PGSSTLFIER
     VTEEDEGVYH CKATNQKGSV ESSAYLTVQG TSDKSNLELI TLTCTCVAAT LFWLLLTLFI
     RKMKRSSSEI KTDYLSIIMD PDEVPLDEQC ERLPYDASKW EFARERLKLG KSLGRGAFGK
     VVQASAFGIK KSPTCRTVAV KMLKEGATAS EYKALMTELK ILTHIGHHLN VVNLLGACTK
     QGGPLMVIVE YCKYGNLSNY LKSKRDLFFL NKDAALHMEP KKEKMEPGLE QGKKPRLDSV
     TSSESFASSG FQEDKSLSDV EEEEDSDGFY KEPITMEDLI SYSFQVARGM EFLSSRKCIH
     RDLAARNILL SENNVVKICD FGLARDIYKN PDYVRKGDTR LPLKWMAPES IFDKIYSTKS
     DVWSYGVLLW EIFSLGGSPY PGVQMDEDFC SRLREGMRMR APEYSTPEIY QIMLDCWHRD
     PKERPRFAEL VEKLGDLLQA NVQQDGKDYI PINAILTGNS GFTYSTPAFS EDFFKESISA
     PKFNSGSSDD VRYVNAFKFM SLERIKTFEE LLPNATSMFD DYQGDSSTLL ASPMLKRFTW
     TDSKPKASLK IDLRVTSKSK ESGLSDVSRP SFCHSSCGHV SEGKRRFTYD HAELERKIAC
     CSPPPDYNSV VLYSTPPI
//
